1. Home
  2. ARCB vs LQDA Comparison

ARCB vs LQDA Comparison

Compare ARCB & LQDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARCB
  • LQDA
  • Stock Information
  • Founded
  • ARCB 1923
  • LQDA 2004
  • Country
  • ARCB United States
  • LQDA United States
  • Employees
  • ARCB N/A
  • LQDA N/A
  • Industry
  • ARCB Trucking Freight/Courier Services
  • LQDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • ARCB Industrials
  • LQDA Health Care
  • Exchange
  • ARCB Nasdaq
  • LQDA Nasdaq
  • Market Cap
  • ARCB 1.6B
  • LQDA 1.9B
  • IPO Year
  • ARCB N/A
  • LQDA 2018
  • Fundamental
  • Price
  • ARCB $71.98
  • LQDA $22.43
  • Analyst Decision
  • ARCB Buy
  • LQDA Strong Buy
  • Analyst Count
  • ARCB 13
  • LQDA 9
  • Target Price
  • ARCB $93.25
  • LQDA $32.11
  • AVG Volume (30 Days)
  • ARCB 340.8K
  • LQDA 2.9M
  • Earning Date
  • ARCB 11-05-2025
  • LQDA 11-12-2025
  • Dividend Yield
  • ARCB 0.67%
  • LQDA N/A
  • EPS Growth
  • ARCB 27.88
  • LQDA N/A
  • EPS
  • ARCB 6.77
  • LQDA N/A
  • Revenue
  • ARCB $4,054,102,000.00
  • LQDA $19,322,000.00
  • Revenue This Year
  • ARCB N/A
  • LQDA $405.58
  • Revenue Next Year
  • ARCB $5.06
  • LQDA $373.93
  • P/E Ratio
  • ARCB $10.63
  • LQDA N/A
  • Revenue Growth
  • ARCB N/A
  • LQDA 30.20
  • 52 Week Low
  • ARCB $55.19
  • LQDA $9.71
  • 52 Week High
  • ARCB $123.26
  • LQDA $29.94
  • Technical
  • Relative Strength Index (RSI)
  • ARCB 52.41
  • LQDA 40.74
  • Support Level
  • ARCB $66.88
  • LQDA $21.35
  • Resistance Level
  • ARCB $70.65
  • LQDA $23.33
  • Average True Range (ATR)
  • ARCB 2.54
  • LQDA 1.27
  • MACD
  • ARCB 0.21
  • LQDA -0.35
  • Stochastic Oscillator
  • ARCB 64.15
  • LQDA 18.69

About ARCB ArcBest Corporation

ArcBest Corp is an integrated logistics company that leverages technology and a full suite of shipping and logistics solutions to meet customers' supply chain needs. The company has two reportable operating segments: Asset-Based, which generates maximum revenue, and Asset-Light. The Asset-Based segment's operations include national, inter-regional, and regional transportation of general commodities through standard, expedited, and guaranteed less-than-truckload services. The Asset-Light segment represents the company's offerings in ground expedite, intermodal, household goods moving, managed transportation, warehousing and distribution, and international freight transportation for air, ocean, and ground.

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

Share on Social Networks: